Knight Therapeutics Inc.

TSX:GUD Voorraadrapport

Marktkapitalisatie: CA$570.5m

Knight Therapeutics Dividend

Dividend criteriumcontroles 0/6

Knight Therapeutics does not have a record of paying a dividend.

Belangrijke informatie

n/a

Dividendrendement

5.2%

Terugkoop Rendement

Totaal aandeelhoudersrendement5.2%
Toekomstig dividendrendementn/a
Dividendgroein/a
Volgende betaaldatum dividendn/a
Ex-dividenddatumn/a
Dividend per aandeeln/a
Uitbetalingsration/a

Recente dividendupdates

Geen updates

Recent updates

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 28
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

May 07
Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Apr 07
Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

Mar 20
Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Mar 02
If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 03
Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

Jan 19
Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

Jan 04
What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Dec 20
A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

Dec 07
The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 02
What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021

Nov 17
Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Insufficient data to determine if GUD's dividends per share have been stable in the past.

Groeiend dividend: Insufficient data to determine if GUD's dividend payments have been increasing.


Dividendrendement versus markt

Knight Therapeutics Dividendrendement versus markt
Hoe verhoudt GUD dividendrendement zich tot de markt?
SegmentDividendrendement
Bedrijf (GUD)n/a
Markt onderkant 25% (CA)1.8%
Markt Top 25% (CA)6.1%
Gemiddelde industrie (Pharmaceuticals)2.3%
Analist prognose (GUD) (tot 3 jaar)n/a

Opmerkelijk dividend: Unable to evaluate GUD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hoog dividend: Unable to evaluate GUD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Winstuitkering aan aandeelhouders

Verdiendekking: Insufficient data to calculate GUD's payout ratio to determine if its dividend payments are covered by earnings.


Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Unable to calculate sustainability of dividends as GUD has not reported any payouts.


Ontdek bedrijven met een sterk dividend